Peitsch Wiebke K, Doerflinger Yvette, Fischer-Colbrie Reiner, Huck Volker, Bauer Alexander T, Utikal Jochen, Goerdt Sergij, Schneider Stefan W
Department of Dermatology, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany ; Helmholtz Group for Cell Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pharmacology, Innsbruck Medical University, Innsbruck, Austria.
PLoS One. 2014 Feb 18;9(2):e89491. doi: 10.1371/journal.pone.0089491. eCollection 2014.
During development and progression of malignant melanoma, an important role has been attributed to alterations of cell-cell adhesions, in particular, to a "cadherin switch" from E- to N-cadherin. We have previously shown that a subtype of melanoma cells express the desmosomal cadherin desmoglein 2 as non-junction-bound cell surface protein in addition to classical cadherins. To study the role of desmoglein 2 in melanoma cells, melanoma lines containing high endogenous amounts of desmoglein 2 were depleted of the protein by RNA interference. Transwell migration and scratch wounding assays showed markedly increased migration upon desmoglein 2 suppression whereas proliferation and viability remained unaltered. In gene expression profiles, desmoglein 2 depletion was associated with overexpression of migration-related genes. Strongest overexpression was found for secretogranin II which has not been reported in melanoma cells before. The bioactive peptide derived from secretogranin II, secretoneurin, is known to exert chemoattractive functions and was demonstrated here to stimulate melanoma cell migration. In summary, we show that desmoglein 2 expression attenuates migration of melanoma cells. The mechanism of desmoglein 2 impaired cell migration is mediated by downregulation of secretogranin II. Loss of desmoglein 2 increases expression of secretogranin II, followed by an enhanced migratory activity of melanoma cells. Our data add a new pathway of regulating melanoma cell migration related to a desmoglein 2-secretogranin II axis.
在恶性黑色素瘤的发生发展过程中,细胞间黏附的改变,尤其是从E-钙黏蛋白到N-钙黏蛋白的“钙黏蛋白转换”,被认为发挥了重要作用。我们之前已经表明,黑色素瘤细胞的一个亚型除了表达经典钙黏蛋白外,还将桥粒钙黏蛋白桥粒芯糖蛋白2作为非连接结合的细胞表面蛋白表达。为了研究桥粒芯糖蛋白2在黑色素瘤细胞中的作用,通过RNA干扰使含有高内源性桥粒芯糖蛋白2的黑色素瘤细胞系中的该蛋白缺失。Transwell迁移实验和划痕损伤实验表明,抑制桥粒芯糖蛋白2后迁移明显增加,而增殖和活力保持不变。在基因表达谱中,桥粒芯糖蛋白2的缺失与迁移相关基因的过表达有关。发现分泌粒蛋白II的过表达最为强烈,此前在黑色素瘤细胞中尚未有相关报道。已知源自分泌粒蛋白II的生物活性肽促胰液素,具有化学吸引功能,在此证明其可刺激黑色素瘤细胞迁移。总之,我们表明桥粒芯糖蛋白2的表达减弱了黑色素瘤细胞的迁移。桥粒芯糖蛋白2损害细胞迁移的机制是由分泌粒蛋白II的下调介导的。桥粒芯糖蛋白2的缺失增加了分泌粒蛋白II的表达,随后黑色素瘤细胞的迁移活性增强。我们的数据增加了一条与桥粒芯糖蛋白2 - 分泌粒蛋白II轴相关的调节黑色素瘤细胞迁移的新途径。